Monday, 2 June 2014

GSK in $350 million deal to develop cancer drugs with UK biotech firm

(Reuters) - GlaxoSmithKline Plc GSK.L has agreed a deal worth more than $350 million with British biotech company Adaptimmune to develop cancer drugs based on novel cell-based therapies.















via Reuters: Health News Read More Here..
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)